Sign up for our newsletter

The suPAR biomarker predicts negative patient outcomes by measuring the immune system’s activation level across diseases.

suPARnostic® is a reliable prognostic tool that enables healthcare professionals to make quick and informed patient triaging decisions with confidence, by making better informed decisions across diseases, backed by reliable data.

At hospital emergency departments, suPAR delivers faster and safer patient discharges, reduces readmissions, avoids unnecessary admissions, and lowers hospital length of stay.

Implementing suPAR in clinical care saves critical resources and valuable time, and results in vastly reduced healthcare costs, more efficient triage, and better patient outcomes.

Sign up for our newsletter to get the latest news and publications on suPAR.

[wpforms id=”5700″ title=”false” countries_mode=”include” countries_input=”” countries_region=”null” cities_mode=”include” cities_input=”” cities_region=”null” states_mode=”include” states_input=”” states_region=”null” zipcodes_mode=”include” zipcodes_input=”” zipcodes_region=”null” radius_mode=”include” ]

“It has become clear that suPAR is a very strong prognostic marker, exceeding the prognostic value of all other routinely measured biomarkers in our hospital.”

Prof. Ove Andersen,
MD, PhD, DmSc, Copenhagen University Hospital Hvidovre, Denmark
suPAR News Vol. 3, June 2020

References

_{1: Thunø M, Macho B, Eugen-Olsen J. suPAR: The molecular crystal ball. Dis Markers. 2009;27(3):157-72.}
_{2: Schultz et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2019, 27:43}
_{3: Eugen-Olsen, J. et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J. Intern. Med. 2010;268, 296–308.}
_{4: Borne Y, Persson M, Melander O,et al. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure butnotatrial fibrillation. European journal of heart failure 2014;16:377-83.}
_{5: Eapen DJ, Manocha P, Ghasemzedah N,et al. Soluble urokinase plasminogen activator receptor level isan independent predictor of the presence and severity ofcoronary artery disease andof future adverse events. Journal of the American Heart Association 2014;3:e001118.}
_{6: Gumus A, Altintas N, Cinarka H,et al. Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD. International journal of chronic obstructive pulmonary disease 2015;10:357-65.}
_{7: Lyngbaek S, Andersson C, Marott JL, et al. Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain. Clinical chemistry 2013;59:1621-9.}
_{8: Lyngbaek S, Marott JL, Moller DV, et al. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. The American journal ofcardiology 2012;110:1756-63.}
_{9: Molkanen T, Ruotsalainen E, Thorball CW, et al. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2011;30:1417-24.}
_{10: Persson M, Ostling G, Smith G,et al. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. Stroke; a journal of cerebral circulation 2014;45:18-23.}
_{11: Raggam RB, Wagner J, Pruller F,et al. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome. Journal of internal medicine 2014;276:651-8.}
_{12: Hayek S, Sever S,Ko Y et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med. 2015 Nov 12; 373(20):1916-25.}
_{13: Reichsoellner M, Raggam RB, Wagner J, Krause R, Hoenigl M. Clinical evaluation ofmultiple inflammation biomarkers for diagnosis and prognosis for patients with systemic inflammatory response syndrome. Journal of clinical microbiology 2014;52:4063-6.}
_{14: Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez-Hoyos M, Santibanez M.Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. Intensive care medicine 2013;39:1945-52.}
_{15: Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver international : official journal of the International Association for the Study of the Liver 2012;32:500-9.}
_{16: Donadello K, Scolletta S, Taccone FS, et al. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients. Journal of critical care 2014;29:144-9.}

Sign up for our newsletter

“It has become clear that suPAR is a very strong prognostic marker, exceeding the prognostic value of all other routinely measured biomarkers in our hospital.”

References

900+

published suPAR studies in leading medical journals

The suPARnostic® brand consists of 3 products:

Quick Triage

TurbiLatex

ELISA Assay

suPAR is used in clinical routine in 48 hospitals

Webinar

Catch COVID-19